



ISSN 0924-9338

March 2018
Vol. 48 – pp. S1–S766

EUROPEAN PSYCHIATRY

THE JOURNAL OF THE EUROPEAN PSYCHIATRIC ASSOCIATION

**Abstracts of the
26th European
Congress of
Psychiatry - 2018**



87432

Full table of contents inside



8TH EPA SUMMER SCHOOL

ABCs OF PSYCHOTHERAPY

APPLY NOW
ON THE EPA WEBSITE
& JOIN US AT
THE NEXT SUMMER SCHOOL !

6-9 SEPTEMBER 2018
STRASBOURG, FRANCE

European Psychiatric Association

www.europsy.net



#EPASummerSchool

EDITORIAL LEADERSHIP

Andrea Fiorillo

Professor of Psychiatry, University of Campania "Luigi Vanvitelli", Largo Madonna delle Grazie, 80138, Naples, Italy.

E-mail: andrea.fiorillo@unicampania.it

Sophia Frangou, MD, PhD, FRCPSych

Professor of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425, Madison Avenue, New York, NY 10029, USA,

Tel.: (01) 212-659-1668; E-mail: sophia.frangou@mssm.edu

Reinhard Heun

Professor of Psychiatry, Radbourn Unit, Royal Derby Hospital, Uttoxeter Road, Derby, DE 223WQ UK, Tel.: (44) 1332-623877;

E-mail: reinhard.heun@derbyshcft.nhs.uk

EDITORIAL OFFICE

EPA Administrative Office

15 avenue de la Liberté, 67000 Strasbourg - France

Phone: +33 388 239 930; E-mail: europeanpsychiatry@gmail.com

EDITORIAL BOARD

P. Boyer (Paris), J.D. Guelfi (Paris), M. Maj (Naples), R. Murray (London), H. Sass (Aachen)

STATISTICAL ADVISORS

A. Heyting (Da Marken), N. Takei (Hamamatsu), B. Falissard (Paris)

FOUNDING EDITORS

P. Boyer (Paris), J.D. Guelfi (Paris), Y. Lecrubier (Paris)

EDITORS EMERITUS

C. Ballus (Barcelona), P. Bech (Copenhagen), C.B. Pull (Luxembourg)

**THE JOURNAL
OF THE
EUROPEAN
PSYCHIATRIC
ASSOCIATION**

www.europsy.net

President: S. Galderisi (Naples)

Past President: W. Gaebel (Düsseldorf)

President Elect: P. Gorwood (Paris)

Secretary General: J. Beezhold (Norwich)

Treasurer: G. Dom (Boechout)

Council of NPAs Chair: T. Kurimay (Budapest)

Secretary For Sections: M. Musalek (Vienna)

Secretary For Education: C. Hanon (Paris)

European Psychiatry (ISSN 0924-9338) 2018 (volumes 47–54) One year, 8 issues. See complete rates at <http://www.europsy-journal.com>

Address order and payment to Elsevier Masson SAS, Service Abonnements, 65, rue Camille-Desmoulins, 92442 Issy-les-Moulineaux cedex: payment by check or credit card (CB, MasterCard, EuroCard or Visa: indicate number and expiration date); by transfer: « La Banque Postale », Centre de Paris, n° RIB : 20041 00001 1904540 H 020 95.

Subscriptions begin 4 weeks after receipt of payment and start with the first issue of the calendar year. Back issues and volumes are available from the publisher. Claims for missing issues should be made within 6 months of publication. Includes air delivery.

Subscriptions – Tel.: (33) 01 71 16 55 99. Fax: (33) 01 71 16 55 77. <http://www.europsy-journal.com>

Publisher – Agnieszka Freda. Tel.: 0031612252117. E-mail: a.freda@elsevier.com

Journal Manager – Kheira Jolivet. Tel.: 33 (0) 1 71 16 50 21. E-mail: EURPSY@elsevier.com

Publishing director – Daniel Rodriguez

Author inquiries

For inquiries relating to the submission of articles (including electronic submission where available) please visit Elsevier's Author Gateway at <http://authors.elsevier.com>. The Author Gateway also provides the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

Subscription conditions, instructions to authors, the contents of each issue as well as the abstracts of the articles published in *European Psychiatry* are available on the journal website: www.europsy-journal.com



Subscribe to European Psychiatry

EPA Membership (100 €) includes an online subscription to the Journal. If you are interested in becoming a member of EPA, please visit <http://www.europsy.net/about-epa/individual-membership>

© 2018 Elsevier Masson SAS. All rights reserved.

Simplified joint stock company with sole shareholder, with a capital of 47 275 384 €. - Registered office: 65, rue Camille-Desmoulins, 92130 Issy-les-Moulineaux. - RCS Nanterre 542 037 031

This journal and the individual contributions contained in it are protected under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works

Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage

Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions

For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Author rights

Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at <http://www.elsevier.com/authorsrights>).

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

For a full and complete Guide for Authors, please refer to the World Wide Web: <http://www.elsevier.com/locate/eurpsy>

Available online at www.sciencedirect.com

ScienceDirect

European Psychiatry has no page charges



Vol. 48, Supplement March 2018

EUROPEAN
PSYCHIATRY

CONTENTS

Abstracted in: BIOSIS/Biological Abstracts, Current Contents/Clinical Medicine and Social & Behavioural Sciences, EMBASE/Excerpta Medica, MEDLINE/Index Medicus, PASCAL/INIST-CNRS, Psychological Abstracts, PsycINFO, PsyLIT, Research Alert, SciSearch

Abstracts of the 26th European Congress of Psychiatry - 2018

Ask the Experts.....	S1
Core Symposium	S4
Debate	S11
ECP Abstracts	S12
Workshop	S15
EFPT/ ECPC-EPA Symposium	S33
Joint Symposium	S34
Symposium	S37
Panel	S66
Plenary Lecture	S68
Presidential Symposium	S70
State of the Art Lecture	S71
Oral Communications	S72
E-Poster Walk	S141
E-Poster Viewing	S453

Methods.– A total of 42 male BALB/c mice were divided into 6 groups of 7 mice, separately. Positive and negative control groups received fluoxetine (20 mg/kg, i.p.) and reserpine (5 mg/kg, i.p.) and vehicle mice received normal saline (1 mg/kg, i.p.), respectively and treatment groups received Papaver rhoeas hydro-alcoholic extract at concentrations of 50, 100, 200 mg/kg, 18 h after administration of reserpine. Mice were then studied with behavioural tests (forced swimming and rotarod). Finally, mice's blood antioxidant capacity was measured.

Results.– Significant difference ($P < 0.001$) in the duration of immobility time between reserpine treated and vehicle groups was obtained. Papaver rhoeas hydro-alcoholic extract at define concentrations, reduced the duration of immobility time and significantly improved blood antioxidant capacity.

Conclusion.– According to the results, Papaver rhoeas can be a good candidate for use as a natural drug with antidepressant effects.

Keywords: Papaver rhoeas hydro-alcoholic extract; Depression; Forced swimming test

Disclosure of interest.– The authors have not supplied their declaration of competing interest.

EV0263

Cerebral folate deficiency in treatment resistant depression: A literature review

S. Kousgaard Khan*, J. Nørgaard Kjær
Psychiatric Research academy section Q, Psychiatric hospital Risskov, Aarhus, Denmark

* Corresponding author.

Introduction.– Approximately 15% of patients with depressive disorders do not respond to any of the current treatments available and are categorized as treatment-resistant. A recent study by Pan et. al. examined patients with treatment resistant depression for metabolic disorders. A greater proportion of the participants had metabolic disorders, cerebral folate deficiency being the most frequent. Treatment of folate deficiency resulted in a decrease of depressive symptoms. The study was limited by a small number of participants.

Objectives.– The aim of this study was to make a review of clinical studies in cerebral folate deficiency and depression.

Methods.– We searched in MEDLINE using the MeSH vocabulary (folic acid, folic acid deficiency, depressive disorder, treatment-resistant) and the phrase: cerebral folate deficiency. Non-clinical studies were excluded.

Results.– We found 771 articles of which 753 were excluded. Earlier studies going back to the 1960's did identify an association between folate deficiency and depression. These studies only concerned peripheral folate deficiency. One recent case-control study included spinal fluid in the tests of folate compounds in patients treatment-resistant depression. They found an association between treatment-resistant depression and cerebral folate deficiency. Treatment with folic acid while continuing the prior antidepressive treatment resulted in a decrease of depressive symptoms.

Conclusion.– Previous studies indicated folic acid as a potential adjuvant therapy to improve inadequate response to antidepressants. However only two articles studied cerebral folate deficiency in treatment-resistant depression and thus the requirement for spinal fluid analysis in diagnosing treatment-resistant depression is still to be determined.

Disclosure of interest.– The authors have not supplied their declaration of competing interest.

EV0264

Comprehensive analysis of suicidal behavior in depressive disorders in cancer patients

H. Kozhyna*, K. Zelenska, V. Mykhaylov, S. Isayenko, V. Koshchii
Kharkiv National Medical University, Psychiatry, narcology and medical psychology, Kharkiv, Ukraine

* Corresponding author.

Recently, the relevance of the problem of depression in cancer practice has increased significantly, where their prevalence ranges from 40 to 60% according to various authors.

The aim of the study.– The study of the phenomenology of suicidal behaviour in depressive disorders in cancer patients.

Material and methods.– for the purpose of studying our goal, we carried out a comprehensive examination of 154 patients of both sexes with an oncological pathology I and II stage in which depression was diagnosed. The main group consisted of 103 patients with signs of suicidal behaviour, control - 51 patients (men) without signs of suicidal behaviour. Malignant neoplasm is a psycho-traumatic factor for the patient, and leads to the development of depressive disorders, and suicidal behaviour. In the clinical picture of depressive disorders in patients with oncological pathology dominated mood depression, the affect of yearning and anxiety, the coverage of the experiences of acute grief in connection with the diagnosis of cancer, with the narrowing of cognitive functions and the domination of the content of mental trauma in consciousness. In the formation of suicidal behaviour of cancer patients with depressive disorders, high rates, according to clinical scales of anxiety and depression, high level of suicidal risk in combination with low level of death consciousness, and suicidologic anamnesis are a leading role.

Disclosure of interest.– The authors have not supplied their declaration of competing interest.

EV0265

Depressive disorders in internally displaced persons

H. Kozhyna*, V. Korostiy, K. Zelenska, V. Mykhaylov, V. Gaponov
Kharkiv National Medical University, Psychiatry, narcology and medical psychology, Kharkiv, Ukraine

* Corresponding author.

Introduction.– According to the Guiding Principles on Internal Displacement, internally displaced persons are persons who have been forced or obliged to leave their homes, in particular as a result of extreme situations, and who have not crossed an state border.

Aim.– to study clinical features of disorders in Internally Displaced Persons.

Methods.– We have a complex psychopathological and psychodiagnostic research 115 IDPs in volunteer center, located at the central train station in Kharkiv.

Results.– There were clinical and psychopathological signs of depressive disorders in Internally Displaced Persons analysed. Anxiety, asthenia, asthenic-apathetic and melancholy variants of depressive disorders in there were clinical and psychopathological signs of depressive disorders in in Internally Displaced Persons analysed. In this study there were the markers of suicide risk for Internally Displaced Persons determined: high suicide risk, low death self-consciousness, high anhedonia level, clinical manifestations of anxiety and depression by The Hospital Anxiety and Depression scale, severe anxiety and depression by The Hamilton Anxiety Rating Scale, major depressive episode by the Montgomery-Asberg Depression Rating Scale. There were approaches to differentiated prevention of suicidal behaviour in